Allwright, Michael
Guennewig, Boris
Hoffmann, Anna E.
Rohleder, Cathrin
Jieu, Beverly
Chung, Long H.
Jiang, Yingxin C.
Lemos Wimmer, Bruno F.
Qi, Yanfei
Don, Anthony S.
Leweke, F. Markus
Couttas, Timothy A.
Funding for this research was provided by:
Medical Research Futures Fund (GA268519)
Brain and Intelligence Science (BISA) Sydney-Fudan University accelerator grant
National Health and Medical Research Council (GNT1162545)
Deputy Vice Chancellor-Start Up Funds, University of Sydney
Moriya Elizabeth Vine Fund
Article History
Received: 20 November 2023
Accepted: 6 February 2024
First Online: 22 February 2024
Competing interests
: The authors declare no competing interests; F.M.L. is a shareholder of curantis UG (Ltd.) and received an Investigator Initiated Trial grant from Endosane Pharmaceuticals GmbH; C.R. is a shareholder of lero bioscience UG (Ltd.); M.A. is the director of Alchem-AI (Ltd.) and a trustee of MyWorld Creative Projects (Charity number: 1197162); B.G. is a director of Pacific Analytics (Pty Ltd.) and SMRTR (Pty Ltd.); B.G. is a an editor at Scientific Reports but was not involved in the peer review or editorial decision-making process for this submission; A.E.H. and C.R. are employees of Endosane Pharmaceuticals GmbH. The remaining authors have nothing to disclose. All research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.